Recent Advances in the Physiological Functions and Biosynthesis of D-Allulose

The 5-gram dose that matters

You already know allulose sweetens like sugar, but this review paper gives formulators a more interesting number. In normal adults, 5 grams of D-allulose significantly suppressed the blood glucose spike from 75 grams of maltodextrin. That goes beyond taste. It points to a rare sugar that can do functional work in a beverage or snack.

The review, published in Frontiers in Microbiology (DOI: 10.3389/fmicb.2022.881037), covers recent advances in both physiological functions and biosynthesis of D-allulose. For ingredient buyers, the production side matters just as much as the health side. Let’s break down both.

Background: allulose beyond sweetness

D-allulose is a rare sugar. It has been known for years as a low-calorie sweetener with a clean taste. But the scientific picture has shifted. Researchers now link it to a much wider set of health effects.

The paper lists anti-obesity, blood glucose-lowering, anti-diabetic, anti-inflammatory, antioxidant, and neuroprotective activity. Some of these effects have stronger data than others. All of them depend on getting consistent, affordable allulose into the supply chain.

What the study did

This is a review article, not a single clinical trial. The authors scanned recent research on D-allulose physiology and biosynthesis, then organized what the field knows so far.

On the physiology side, they summarized evidence across different models and human studies. On the production side, they looked at two main biosynthetic strategies: the Izumoring strategy and the DHAP-dependent aldolase strategy. Izumoring uses enzymes to rearrange cheap sugars into rare sugars. The aldolase route builds allulose from small phosphate-containing molecules. Each approach has different implications for yield, cost, and scale-up.

Key findings

The most practical finding for formulators is the glycemic response data. A small dose of allulose—5 grams—blunted a much larger carbohydrate load. That’s a useful signal. You don’t need to swap 50 grams of allulose into a formula to see a metabolic effect. A moderate amount may be enough.

Here’s how the review’s reported effects line up with formulation relevance:

Area	What the review reports	Why it matters
Glycemic control	5 g D-allulose suppressed blood glucose elevation from 75 g maltodextrin in normal adults	Supports low-glycemic and diabetic-friendly product concepts
Anti-obesity / anti-diabetes	Listed among allulose’s physiological effects	Useful for weight-management positioning
Inflammation and antioxidant	Reported as physiological benefits	Early potential for functional foods
Neuroprotection	Included in the review’s scope	A newer angle, worth watching

No single study answers every formulation question. But the evidence points in one direction: allulose is not just a rare sugar molecule. It behaves like a functional carbohydrate at relatively low inclusion levels.

What it means for manufacturers

If you currently treat allulose as a 1:1 sugar substitute, this paper suggests a second way to use it. You can formulate around a specific active dose, say 5 grams per serving, and communicate glucose moderation as the benefit. The dose doesn’t have to replace all the sugar in a product. It can work alongside other sweeteners.

For buyers, the biosynthesis review is a reminder to ask technical questions. Which enzyme route does your supplier use? Is the process based on Izumoring or DHAP-dependent aldolases? What are the conversion yields and purification costs? These factors affect price, availability, and product consistency. Allulose supply has improved in recent years, but not all production routes perform equally at scale.

The review also hints at a future where allulose could be positioned beyond the sweetener aisle. Anti-inflammatory and neuroprotective effects are not ready for front-of-pack claims. Yet they inform next-generation product development. Keep them on the R&D radar.

FAQ

Does 5 g of allulose really blunt a carbohydrate spike? The review reports exactly that result in normal adults. The carbohydrate challenge was 75 g of maltodextrin, so the test conditions were substantial. Formulate your own product and test it, of course. The matrix matters.

Is allulose a sweetener or a functional ingredient? It’s both. The sweetness gets consumers in the door. The physiological effects—especially glucose response—give formulators a reason to dial in a specific dose per serving.

What should I ask my supplier about biosynthesis? Ask which enzymatic strategy they use. Izumoring and DHAP-dependent aldolase routes differ in raw materials, enzyme efficiency, and downstream processing. Those differences show up in price and reliability.

The paper’s real message is simple. Allulose acts on blood glucose at 5 grams, and production technology continues to evolve. That combination creates room for formulators willing to look past the sweetener category.